HealthCDC

Explainer

Updated

Who can get the RSV vaccine?

Key facts

For babies, the CDC recommends either a maternal vaccine during weeks 32 through 36 of pregnancy or an RSV antibody given to the infant, and says most babies do not need both.

The Centers for Disease Control and Prevention recommends a single dose of RSV vaccine for all adults ages 75 and older and for adults ages 50 to 74 who are at increased risk of severe RSV illness. For babies, the CDC recommends one of two options: a maternal RSV vaccine given during pregnancy, or a long-acting RSV antibody given to the baby. RSV symptoms and when to call a doctor are covered in What are the symptoms of RSV?

Who is covered, group by group

As listed on the CDC's adult guidance, pregnancy guidance and infant page. Timing applies to most of the continental United States.

GroupWhat the CDC recommendsWhen
Adults 75 and olderOne dose of any of the three licensed RSV vaccinesAny time, best in August to October
Adults 50 to 74 at increased riskOne dose of any of the three licensed RSV vaccinesAny time, best in August to October
Pregnant women at 32 through 36 weeksOne dose of Pfizer's AbrysvoSeptember through January
Babies younger than 8 months whose mothers were not vaccinatedOne dose of nirsevimab or clesrovimabOctober through March
Children 8 to 19 months at increased risk, entering a second RSV seasonOne dose of nirsevimabShortly before the second season

Adults 50 and older

The three vaccines licensed for adults are GSK's Arexvy, Moderna's mResvia and Pfizer's Abrysvo, and the CDC has no preference among them. Its adult guidance lists these conditions as raising the risk of severe RSV illness for people 50 to 74:

  • Chronic heart disease, such as heart failure, coronary artery disease or congenital heart disease, not counting high blood pressure alone
  • Chronic lung or respiratory disease, such as COPD, emphysema, asthma, interstitial lung disease or cystic fibrosis
  • End-stage kidney disease or dependence on dialysis
  • Diabetes with complications such as chronic kidney disease, nerve or eye damage, or diabetes treated with insulin or an SGLT2 inhibitor
  • Neurologic or neuromuscular conditions that weaken breathing muscles or impair airway clearance
  • Chronic liver disease, such as cirrhosis
  • Chronic blood conditions, such as sickle cell disease or thalassemia
  • Severe obesity, a body mass index of 40 or higher
  • Moderate or severe immune compromise
  • Living in a nursing home
  • Other conditions or risk factors a healthcare provider judges would raise the risk, including frailty or living in a remote or rural community where getting care for severe RSV is difficult

The same guidance says a patient's own statement is enough evidence of a risk factor, and that vaccinators should not deny vaccination for lack of medical documentation. RSV vaccines can be given at the same visit as other adult vaccines.

The FDA has approved Abrysvo and mResvia for adults 18 to 49 at increased risk, but the CDC's adult guidance says the advisory committee and the CDC are still reviewing evidence for that age group and does not include it in the recommendation.

One dose, not every year

The RSV vaccine is not currently an annual vaccine, the CDC's page for adults says, and protection lasts more than one year. Anyone who has already received an RSV vaccine should not get another one at this time. The CDC says one dose protects adults 50 and older for at least two years, and that it will evaluate how long protection lasts and may update the recommendations.

Pregnancy

The CDC's pregnancy guidance recommends one dose of Pfizer's Abrysvo from 32 weeks 0 days through 36 weeks 6 days of pregnancy, from September through January in most of the continental United States. The cases a reader meets next:

  • Past 36 weeks 6 days. The CDC says those women should not be vaccinated, and the baby should get an RSV antibody instead.
  • Outside September through January. Providers should not give the vaccine outside that window unless the person lives where RSV circulation is less predictable, which the CDC names as Alaska and tropical climates including southern Florida, Guam, Hawaii, Puerto Rico, the U.S.-affiliated Pacific Islands and the U.S. Virgin Islands.
  • A later pregnancy. The CDC does not recommend another dose for anyone vaccinated during a previous pregnancy. The baby should get an RSV antibody instead, the CDC's infant page says.
  • Which vaccine. Abrysvo is the only RSV vaccine recommended in pregnancy, and the CDC says Arexvy and mResvia are not approved for use during pregnancy.
  • Other vaccines. The maternal RSV vaccine can be given at the same visit as Tdap, COVID-19 or flu vaccines.

Infants and young children

Nirsevimab and clesrovimab are monoclonal antibodies, not vaccines, the CDC's infant guidance says, and the adult RSV vaccines are not approved for infants or young children. The CDC recommends an infant antibody for babies younger than 8 months who are born during or entering their first RSV season if the mother did not get the RSV vaccine during pregnancy, if her vaccination status is unknown, or if the baby was born within 14 days of her vaccination.

Babies born from October 1 through March 31 should get the antibody within one week after birth, ideally during the birth hospitalization. For babies born April through September, the CDC says the best time is shortly before the season begins, such as October or November.

Nirsevimab, but not clesrovimab, is recommended for children 8 to 19 months entering their second RSV season who have chronic lung disease of prematurity that needed medical support in the prior 6 months, severe immunocompromise, cystic fibrosis with severe lung disease or low weight for length, or who are American Indian or Alaska Native. The CDC says children 8 months and older who are not at increased risk should not get an infant antibody, and it does not recommend nirsevimab for anyone 20 months or older.

Who should not get it

The CDC's page for adults says anyone who has had a severe allergic reaction to any component of an RSV vaccine should not get one, and that a person with a moderate or severe illness should wait until recovering, while a minor illness such as a cold is not a reason to wait. On the infant page, the CDC lists children with a serious allergic reaction to any component of either infant antibody, and babies already protected because their mother got the maternal vaccine, as those who should not get an infant antibody.

What changed and when

  • May 2023 and June 2024. The FDA licensed Arexvy and Abrysvo in May 2023 and mResvia in June 2024, the CDC's page for adults says.
  • April 15 to 16, 2025. The Advisory Committee on Immunization Practices recommended a single dose for adults 50 to 59 at increased risk of severe RSV, and the HHS Secretary adopted it on June 25, 2025, according to the CDC's ACIP recommendations page.
  • June 25 to 26, 2025. The committee recommended clesrovimab for infants younger than 8 months not protected by maternal vaccination, with no preference between it and nirsevimab, and the CDC Director adopted it on August 4, 2025, the same page says.
  • December 31, 2025. The CDC's infant guidance says palivizumab will no longer be available starting that date.
  • February 24, 2026. The CDC last updated its adult guidance, which keeps the single dose for all adults 75 and older and for adults 50 to 74 at increased risk.

Have another question?